VLS Valneva SE

VALNEVA Declaration of shares and voting rights: July 31, 2025

VALNEVA Declaration of shares and voting rights: July 31, 2025

VALNEVA

Declaration of shares and voting rights

July 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: August 5, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**






170,188,190 



ordinary shares with a par value of €0.15 each
186,313,413 Transfer into bearer form of 2,100 shares with double voting rights 

Double voting rights granted on 1,768 ordinary shares


 



On July 17, 2025

Between July 26 & July 31, 2025





 
186,189,091

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: July 31, 2025

VALNEVA Declaration of shares and voting rights: July 31, 2025 VALNEVA Declaration of shares and voting rights July 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: August 5, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized ...

 PRESS RELEASE

VALNEVA Déclaration d’actions et de droits de vote : 31 juillet 2025

VALNEVA Déclaration d’actions et de droits de vote : 31 juillet 2025 VALNEVA Déclaration d’actions et de droits de vote 31 juillet 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 5 août 2025 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droits de vote suspendus* Origine de la variation Date à laquelle cette va...

Damien Choplain ... (+2)
  • Damien Choplain
  • Oscar Haffen Lamm

Valneva: resuming coverage

As of 30th July 2025, we resume coverage of Valneva, which will now be followed by Damien Choplain. We maintain our Buy rating and our EUR10 PT.

Valneva SE: 1 director

A director at Valneva SE bought 20,000 shares at 2.540EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

Valneva Announces Lifting of European Medicines Agency’s Temporary Res...

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly Saint Herblain (France), July, 11 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC). The committee initiated its review at the beginning of May following the occurrence of serious sid...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch